Funder
Massey University Research Funds
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,General Medicine
Reference36 articles.
1. Roques BP, Fournié-Zaluski M-C, Wurm M. Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov. 2012;11:292–310.
2. Rougeot C, Robert F, Menz L, Bisson J-F, Messaoudi M. Systemically active human opiorphin is a potent yet non-addictive analgesic without drug tolerance effects. J Physiol Pharmacol. 2010;61:483–90.
3. Wisner A, Dufour E, Messaoudi M, Nejdi A, Marcel A, Ungeheuer M-N, et al. Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci U S A. 2006;103:17979–84. pnas.org
4. Pinto M, Rougeot C, Gracia L, Rosa M, García A, Arsequell G, et al. Proposed bioactive conformations of opiorphin, an endogenous dual APN/NEP inhibitor. ACS Med Chem Lett. 2012;3:20–4.
5. Popik P, Kamysz E, Kreczko J, Wróbel M. Human opiorphin: the lack of physiological dependence, tolerance to antinociceptive effects and abuse liability in laboratory mice. Behav Brain Res. 2010;213:88–93.